^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    thrombospondin-1 mimetic (ABT-510)

    i
    Other names: ABT-510
    Associations

    News

    Trials
    Company:
    AbbVie
    Drug class:
    Angiogenesis inhibitor, VEGF inhibitor, Hepatocyte growth factor inhibitor, FGF inhibitor, IL-8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Preclinical Evaluation of CD36-Targeting Antiangiogenic Peptide ABT-510 for Near-Infrared Fluorescence Molecular Imaging of Colorectal Cancer. (PubMed, Anal Chem)
    Furthermore, MPA-PEG-r-ABT-510 exhibited an antiangiogenic effect via tube information assay with human umbilical vein endothelial cells. Overall, MPA-PEG-r-ABT-510 presents rapid and precise tumor delineation characteristics, thereby making it a desirable tool for CRC imaging and surgical navigation.
    Preclinical • Journal
    |
    CD36 (thrombospondin receptor)
    |
    thrombospondin-1 mimetic (ABT-510)